Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia

Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia

This phase I trial conducted in Japanese patients with acute myeloid leukemia evaluated the safety, maximum tolerated dose and pharmacokinetics of volasertib (BI 6727), a selective Polo-like kinase inhibitor. The primary endpoints were the maximum tolerated dose of volasertib and the incidence of do...

Saved in:

书目详细资料
Main Authors:	Yukio Kobayashi, Takahiro Yamauchi, Hitoshi Kiyoi, Toru Sakura, Tomoko Hata, Kiyoshi Ando, Aiko Watabe, Akiko Harada, Tillmann Taube, Yasushi Miyazaki, Tomoki Naoe
格式:	Artigo
语言:	英语
出版:	2015
在线阅读:	https://doi.org/10.1111/cas.12814 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cas.12814
标签:	添加标签没有标签, 成为第一个标记此记录!

相似书籍

Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia
由: Adachi, Yoshiya, et al.
出版: (2017)

Strategic and Statistical Considerations on the QT Assessment of Volasertib
由: Wallenstein, Gudrun, et al.
出版: (2017)

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
由: Gjertsen, B T, et al.
出版: (2015)

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
由: Bjørn Tore Gjertsen, et al.
出版: (2014)

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
由: C-C. Lin, et al.
出版: (2014)

The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells
由: Dong, Jianwen, et al.
出版: (2018)

Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies
由: Platzbecker, Uwe, et al.
出版: (2022)

Initial Testing (Stage 1) of the Polo-Like Kinase Inhibitor Volasertib (BI 6727), by the Pediatric Preclinical Testing Program
由: Gorlick, Richard, et al.
出版: (2013)

Initial testing (stage 1) of the polo‐like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program
由: Richard Görlick, et al.
出版: (2013)

Gene mutations of acute myeloid leukemia in the genome era
由: Tomoki Naoe, et al.
出版: (2013)

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
由: Lin, C-C, et al.
出版: (2014)

Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas
由: Murga-Zamalloa, Carlos, et al.
出版: (2017)

Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia
由: Dorothea Rudolph, et al.
出版: (2015)

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
由: Awada, Ahmad, et al.
出版: (2015)

Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo
由: Cholewa, Brian D., et al.
出版: (2016)

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
由: Döhner, Hartmut, et al.
出版: (2021)

Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia
由: Akihiro Tomita, et al.
出版: (2013)

Volasertib for AML: clinical use and patient consideration
由: Hao, Zhonglin, et al.
出版: (2015)

Volasertib preclinical activity in high-risk hepatoblastoma
由: Kats, Dina, et al.
出版: (2019)

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
由: Döhner, Hartmut, et al.
出版: (2014)

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
由: Hartmut Döhner, et al.
出版: (2014)

Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia
由: Gopalakrishnan, Bhavani, et al.
出版: (2018)

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
由: Van den Bossche, Jolien, et al.
出版: (2019)

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
由: Walter M. Stadler, et al.
出版: (2013)

Analysis of the oligomeric states of nucleophosmin using size exclusion chromatography
由: Sakashita, Gyosuke, et al.
出版: (2018)

Nucleophosmin: A versatile molecule associated with hematological malignancies
由: Tomoki Naoe, et al.
出版: (2006)

Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo
由: Zheng, Di-Wei, et al.
出版: (2016)

Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo [Retraction]
出版: (2020)

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
由: Chen, Fangli, et al.
出版: (2016)

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
由: Fangli Chen, et al.
出版: (2016)

Mutations in the Nucleolar Phosphoprotein, Nucleophosmin, Promote the Expression of the Oncogenic Transcription Factor MEF/ELF4 in Leukemia Cells and Potentiates Transformation
由: Ando, Koji, et al.
出版: (2013)

Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib
由: Hong, Mei, et al.
出版: (2014)

B-cell precursors differentiated from cord blood CD34(+) cells are more immature than those derived from granulocyte colony-stimulating factor-mobilized peripheral blood CD34(+) cells
由: Hirose, Yuka, et al.
出版: (2001)

Chimeric antisense RNA derived from chromosomal translocation modulates target gene expression
由: Sugimoto, Takumi, et al.
出版: (2012)

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment
由: Emi Goto, et al.
出版: (2011)

Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all‐<i>trans</i> retinoic acid
由: Kunio Kitamura, et al.
出版: (2000)

Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia
由: Yosuke Minami, et al.
出版: (2003)

Large-Scale Label-Free Comparative Proteomics Analysis of Polo-Like Kinase 1 Inhibition via the Small-Molecule Inhibitor BI 6727 (Volasertib) in BRAF(V600E) Mutant Melanoma Cells
由: Cholewa, Brian D., et al.
出版: (2014)

Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature
由: Takeshita, Akihiro, et al.
出版: (2020)

Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo
由: Schnerch, Dominik, et al.
出版: (2017)